Why the study?
What are the clinical and subclinical pulmonary effects of amiodarone therapy?
Population
34 patients taking amiodarone in a prospective study, along with 4 additional patients diagnosed with…
Design
Cohort
Authors
Loading...
Subclinical TLCO declines may flag amiodarone toxicity risk; leaves open optimal monitoring thresholds in larger cohorts.
What are the clinical and subclinical pulmonary effects of amiodarone therapy?
Clinical and subclinical pulmonary toxicity from amiodarone is common, with subclinical lung function changes often being reversible upon dose reduction.
Adams et al. (1986) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: